Telescope Innovations (TELI) Planet MicroCap Las Vegas 2026 summary
Event summary combining transcript, slides, and related documents.
Planet MicroCap Las Vegas 2026 summary
18 Jun, 2026Innovation and technology focus
Developing physical AI and self-driving laboratories for high-value specialty chemistry, enabling autonomous process optimization and rapid chemical process development.
Automation tools use design of experiments and robotic systems to conduct, monitor, and optimize chemical reactions, providing real-time data to AI models.
Self-driving labs offer 24/7 operation, significant energy efficiency, and reduce R&D costs and time to market for pharmaceuticals.
Technology enables pharma companies to repatriate R&D, improve data collection for regulatory approval, and pursue smaller or personalized drug markets.
Automation is being adopted across pharma, chemical, and clean tech industries, with major investments in lab automation.
Commercialization and partnerships
Products are developed in collaboration with top pharma companies and distributed globally through a partnership with METTLER TOLEDO, reaching 35 countries.
The first product, funded by a consortium of leading pharma firms, is now used by 15 of the top 20 companies, generating recurring revenue and high gross margins.
Self-driving lab modules are being deployed by major clients like Pfizer and top European pharma firms, with product prices ranging from CAD 500,000 to CAD 2 million.
The company leverages its scientific team, including Nobel laureates, to drive innovation and credibility.
Financial performance and outlook
Achieved 80% year-over-year revenue growth through three quarters, with a trailing 12-month growth rate of 110%.
Projected to finish the year with CAD 9–9.4 million in revenue, with a market cap of about $50 million USD.
Raised CAD 6.5 million in October last year, with no immediate need for further fundraising due to ongoing income and grants.
Revenue streams include contract research, product sales, and future licensing, with clean energy applications providing additional upside.
Latest events from Telescope Innovations
- Automation-driven R&D platforms and global partnerships fuel rapid growth and innovation.TELI
Corporate presentation19 Jun 2026 - Revenues surged 80% year-over-year, fueled by SDL growth and new major contracts.TELI
Q3 202616 Jun 2026 - Year-to-date revenues exceeded last year's total, fueled by strong product sales and engagement.TELI
Q3 202411 Jun 2026 - 57% revenue growth and key pharma partnerships fueled innovation and reduced EBITDA loss.TELI
Q4 202411 Jun 2026 - Q1 revenue hit $1.2M, with strategic investments driving growth and innovation.TELI
Q1 202511 Jun 2026 - Revenue up 46% year-over-year, with strategic growth in AI labs and battery tech.TELI
Q2 202511 Jun 2026 - Revenue rose to $1.4M in Q3 FY2025, with strong DirectInject-LC sales and new tech milestones.TELI
Q3 202511 Jun 2026 - Revenue up 32% to $5.8M, driven by record sales and global expansion initiatives.TELI
Q4 202511 Jun 2026 - Q1 FY2026 revenue surged 125% year-over-year, with strong growth in product and research services.TELI
Q1 202611 Jun 2026